With the aging of the population, the proportion of older patients with cancer is increasing. The treatment of older patients with cancer is challenging owing to frailty, comorbidities, and the exclusion from most clinical studies. Green therapy, using low-injury, sustainable, repeatable, and individualized treatment methods—such as minimally invasive surgery and traditional Chinese medicine—provides a new option for patients with cancer who are intolerant or have failed in conventional treatment. This article summarizes the safety and effectiveness of minimally invasive surgery, such as radiofrequency ablation, microwave ablation, cryoablation, and vascular interventional therapy, in older patients with tumors, as well as external treatment of traditional Chinese medicine in clinical practice to provide a basis for green treatment of tumors. Prospective clinical trials should be performed on older patients with cancer to provide high-level evidence-based medical evidence for the treatment of these patients. Furthermore, a clinical prediction model of green treatment based on real-world data should be constructed for older patients with cancer to provide a foundation for clinical medical decision-making. Basic researches should be conducted to explore the mechanism of green tumor treatment.
- Article type
- Year
- Co-author
Open Access
Issue
Open Access
Opinion Paper
Issue
Immune checkpoint inhibitors (ICPI) have shown considerable promise in the treatment of tumors. However, immune-related adverse events (irAEs) caused by ICPI have been reported in nearly every organ system. Whilst this represents a new challenge in the field of cancer treatment, traditional Chinese medicine (TCM) provides benefits in the treatment of irAEs. This article reviews the studies of the treatment of immune-related gastrointestinal diseases and dermatosis with TCM and introduces the collaborative efforts between China and France in the implementation of TCM for the treatment of irAEs.
Open Access
Original Article
Issue
This intervention has been shown to be clinically efficacious and safe. The aim of this study was to determine the effect of different intervention times on the efficacy of gastroparesis external application prescription versus placebo for the treatment of gastrointestinal tumor postoperative, postsurgical gastroparesis.
A multicenter, randomized, double-blind, placebo controlled phase Ⅲ clinical trial was designed to demonstrate superiority and conducted at four grade 3A hospitals in Beijing. Patients diagnosed with gastrointestinal tumor postsurgical gastroparesis and local cold syndrome in the abdomen were enrolled and received conventional treatment (nutritional support, gastrointestinal decompression, and prokinetic medication). Treatment and control groups respectively received gastroparesis external application prescription or placebo acupoint application over a treatment course of 14 days or until the primary efficacy endpoint (clinical efficiency) was achieved.
A total of 120 patients were enrolled in the treatment and control groups (n = 60 per group), and 15 patients dropped out of the study because of skin allergies (n = 7) or poor efficacy (n = 8). The efficacy among patients in Class B of Group A(treatment group) was marginally better than that of Group B (control group) (64.28% vs. 55.56%) although the difference between the two groups was not significant. However, the efficacy among patients in Class C of Group A was significantly better than that of Group B (79.49% vs. 43.33%). For Group A, the time for patients in the three classes to achieve the efficacy endpoint increased significantly with disease progression (3.00, 6.78, and 8.29 days for Class A, B, and C, respectively).
Gastroparesis external application prescription can effectively treat gastrointestinal tumor postsurgical gastroparesis and may be more efficacious in progressive disease compared placebo. Patients with gastrointestinal tumor postsurgical gastroparesis should therefore undergo intervention at an earlier stage.
京公网安备11010802044758号